Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1544 views | HTML 2448 views | ?
Joseph Dosch1,*, Elizabeth Ziemke1,*, Shanshan Wan2, Kathryn Luker1, Theodore Welling2, Karin Hardiman2, Eric Fearon3, Suneetha Thomas4, Matthew Flynn4, Jonathan Rios-Doria4, Robert Hollingsworth4, Ronald Herbst4, Elaine Hurt4,# and Judith Sebolt-Leopold1,#
1Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA
2Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA
3Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
4Department of Oncology Research, MedImmune, LLC, Gaithersburg, MD 20878, USA
*These authors contributed equally to this work
Judith Sebolt-Leopold, email: [email protected]
Keywords: ADAM17, TACE, colorectal, stem cell, Notch
Received: November 24, 2016 Accepted: April 03, 2017 Published: May 10, 2017
ADAM17 (a disintegrin and metalloproteinase 17)/TACE (TNFα converting enzyme) has emerged as a potential therapeutic target in colorectal cancer (CRC) and other cancers, due in part to its role in regulating various tumor cell surface proteins and growth factors and cytokines in the tumor microenvironment. The emergence of MEDI3622, a highly potent and specific antibody-based ADAM17 inhibitor, has allowed testing of the concept that targeting ADAM17 may be an important new therapeutic approach for CRC patients. We demonstrate that MEDI3622 is highly efficacious on tumor growth in multiple human CRC PDX models, resulting in improved survival of animals bearing tumor xenografts. MEDI3622 was further found to impact Notch pathway activity and tumor-initiating cells. The promising preclinical activity seen here supports further clinical investigation of this treatment approach to improve therapeutic outcome for patients diagnosed with metastatic CRC, including patients with KRAS-mutant tumors for whom other therapeutic options are currently limited.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.